Ketorolac Tromethamine
Product Images NDC 51662-1488

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ketorolac Tromethamine (NDC 51662-1488). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Adverse 1 (Adverse 1)

This is a list of different gastrointestinal and other experiences that a person may have. The gastrointestinal experiences include abdominal pain, constipation/diarrhea, dyspepsia, flatulence, gastrointestinal fullness, gastrointestinal ulcers (gastric/duodenal), gross bleeding/perforation, heartburn, nausea, stomatitis, and vomiting. The other experiences include abnormal renal function, anemia, dizziness, drowsiness, edema, elevated liver enzymes, headaches, hypertension, increased bleeding time, injection site pain, pruritus, purpura, rashes, tinnitus, and sweating.*

FDA Label Image

Adverse 2 (Adverse 2)

FDA Label Image

Boxed Warning (Boxed Warning)

FDA Label Image

Clinical 1 (Clinical 1)

Table 1 shows the approximate average pharmacokinetic parameters following oral, intramuscular, and intravenous doses of Ketorolac Tromethamine. The table includes information on bioavailability, T max, C max, C min, e avg., and V g. The units of measurement are not clear.*

FDA Label Image

Clinical 2 (Clinical 2)

This text provides pharmacokinetic data on a drug, including the percentage of the dose excreted in feces and urine, plasma protein binding, time-to-peak plasma concentration, and volume of distribution. The data was obtained from pharmacokinetic studies in normal volunteers who either took the drug orally, intramuscularly, or intravenously. The average plasma concentration is not applicable because the drug is only recommended as a single dose. The mean value for volume of distribution was simulated from observed plasma concentration data.*

FDA Label Image

Clinical 3 (Clinical 3)

This appears to be a table showing the influence of age, liver and kidney function on the clearance and half-life of ketorolac tromethamine in adult populations. The table contains information on subjects such as normal subjects, healthy elderly subjects, patients with hepatic dysfunction, renal impairment, and renal dialysis patients. The data includes age ranges, mean values for clearance and terminal half-life in oral and IM administrations, and serum creatinine levels.*

FDA Label Image

Serialized Labeling (Serialized Labeling)

This is the package insert provided by manufacturer for Ketorolac Tromethamine Injection, USP, which is for intramuscular use only. The package contains a 2 mL single-dose vial of the drug labeled as ADNS17 with the NDC code 72266-119-01. The package should be used as directed in the insert. It is distributed by HF Acquisition Co., LLC based in Mukilteo, WA 98275. No additional information availabledue to lack of clarity in the -recognized text.*

FDA Label Image

Structure (Structure)

FDA Label Image

Vial Label (Vial Label)

This is a product information document for an intramuscular injection with the name Ketorolac Tromethamine Injection, produced by FOSUNPHARMA, and containing 60mg/2mL of Ketorolac Tromethamine. It is available in a Single-Dose Vial presentation with an NDC number of 72266-119-01. Use of this injection is restricted to intramuscular administration only.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.